Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Malignant Neoplasm of Breast|CNS Malignancy|Malignant Neoplasm of Gastrointestinal Tract|Genitourinary Neoplasms Malignancy and Gender Unspecified|Head and Neck Neoplasms|Melanoma|Malignant Neoplasm of Thorax
Interventions: DRUG: Alisertib|DRUG: Pazopanib
Sponsor: University of Illinois at Chicago
Collaborators: Millennium Pharmaceuticals, Inc.